Report Overview

The Metabolic Disorders drugs market size in Kenya stood at around USD xx billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.

Metabolic Disorders occur when the normal metabolic processes of the body are disturbed. These can be inherited or acquired. Metabolic Disorders can affect the breakdown of lipids, amino acids or carbohydrates. Diabetes is the most common glycogen metabolism disorder in Kenya. The World Health Organization (WHO) estimates that the prevalence of diabetes in Kenya at 3.3% and predicts a rise to 4.5% by 2025. Higher rates of diabetes are found in urban areas. Kenya has seen increase in abdominal obesity, poor dietary habits, excess alcohol consumption and physical inactivity. One in four Kenyans aged 1869years have elevated blood pressure. The prevalence of hypertension is higher among women and urban residents than among men and rural residents.



Market Drivers

The market is majorly driven by the rising burden of Metabolic Disorders like Diabetes, Obesity and elevated blood pressure due to hypercholesterolemia. According to a study, the prevalence rates of pre-hypertension and hypertension were 49.0% and 31.6% in men and 43.7% and 20.1% in women, respectively, while those of pre-diabetes and diabetes were 8.4% and 8.0% in men and 11.6% and 7.4% in women, respectively.

Increasing initiatives by Government of Kenya by Implementation of National Diabetes Strategy in 2015 has led to establishment of hospital diabetes clinics in nine provinces of the country. A Diabetes Education Programme has also been implemented for healthcare staff.

Kenya has developed a more positive attitude to prevention and public health, increasing the Total Health Expenditure from 9% in 2001 to 23% in 2010.

Diabetes requires long-term follow up, with uninterrupted access to medication and specialist care. Low levels of public awareness, high cost of Insulin, non-adherence to treatment, poor behaviours towards diabetes and unwillingness to adopt healthier lifestyles are hindering growth of metabolic disorders drug market.